CMA Sent Back To The Drawing Board In £89M Pfizer Case
An appeals court ruled Tuesday that the U.K.'s competiton watchdog must review the evidence again in its £89.4 million ($114.7 million) excessive pricing case against Pfizer, but said that the agency had...To view the full article, register now.
Already a subscriber? Click here to view full article